Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively generate RNA ligands for TLR7 activation
2024 · Immunity · 42 citations
https://doi.org/10.1016/j.immuni.2024.04.010
I
Ignazio Piseddu
LMU Klinikum(DE)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
87
Papers
579
Citations
10
h-index
10
i10-index
Ignazio Piseddu is an academic researcher from LMU Klinikum. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Hepatocellular Carcinoma Treatment and Prognosis & Colorectal Cancer Treatments and Studies. The author has an h-index of 10, co-authored 74 publications.
ORCID: 0000-0001-8331-9778Papers by this author
worksMutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
2024 · Nature Communications · 14 citations
https://doi.org/10.1038/s41467-024-45378-w
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
2024 · JHEP Reports · 14 citations
https://doi.org/10.1016/j.jhepr.2024.101065
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
2024 · Frontiers in Immunology · 13 citations
https://doi.org/10.3389/fimmu.2023.1326078
Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma
2022 · Molecular Cancer · 9 citations
https://doi.org/10.1186/s12943-022-01641-6
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity
2025 · JHEP Reports · 2 citations
https://doi.org/10.1016/j.jhepr.2025.101513
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat